Search icon

THERAPYX, INC.

Branch
Company claim

Is this your business?

Get access!

Company Details

Name: THERAPYX, INC.
Legal type: Foreign Corporation
Status: Inactive
Standing: Good
Profit or Non-Profit: Profit
File Date: 23 Jun 2015 (10 years ago)
Authority Date: 23 Jun 2015 (10 years ago)
Last Annual Report: 21 Mar 2023 (2 years ago)
Branch of: THERAPYX, INC., NEW YORK (Company Number 2683576)
Organization Number: 0925652
Principal Office: 1576SWEET HOME ROAD, SUITE 102A, 2468 Grinstead Dr., Suite 1, AMHERST, NY 14228
Place of Formation: NEW YORK

Director

Name Role
NEJAT EGILMEZ Director

Vice President

Name Role
NEJAT EGILMEZ Vice President

Registered Agent

Name Role
KY SECRETARY OF STATE Registered Agent

Form 5500 Series

Employer Identification Number (EIN):
161613097
Plan Year:
2022
Number Of Participants:
15
Sponsors Telephone Number:
Plan Year:
2021
Number Of Participants:
13
Sponsors Telephone Number:
Plan Year:
2020
Number Of Participants:
12
Sponsors Telephone Number:
Plan Year:
2019
Number Of Participants:
12
Sponsors Telephone Number:

Filings

Name File Date
Certificate of Withdrawal 2023-12-12
Principal Office Address Change 2023-03-21
Annual Report 2023-03-21
Annual Report 2022-05-27
Annual Report 2021-04-12

USAspending Awards / Financial Assistance

Date:
2022-02-22
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
OMV VACCINE AGAINST GONORRHEA - ABSTRACT GONORRHEA IS A GENITAL TRACT INFECTION CAUSED BY NEISSERIA GONORRHOEAE, WHICH CAN BE ACQUIRED REPEATEDLY AND DOES NOT NATURALLY INDUCE A STATE OF SPECIFIC PROTECTIVE IMMUNITY AGAINST REINFECTION. DESPITE PUBLIC HEALTH MEASURES, GONORRHEA PERSISTS AT AN UNACCEPTABLY HIGH FREQUENCY, AND THERE IS NO VACCINE AGAINST IT. THE CONTINUING EMERGENCE OF ANTIBIOTIC RESISTANCE THREATENS TO RENDER GONORRHEA UNTREATABLE. OUR FINDINGS HAVE REVEALED THAT N. GONORRHOEAE SUBVERTS THE IMMUNE SYSTEM FOR ITS OWN BENEFIT BY INDUCING HIGH LEVELS OF THE IMMUNO-REGULATORY CYTOKINE, INTERLEUKIN-10 (IL-10). USING THE ESTABLISHED MURINE MODEL OF VAGINAL GONOCOCCAL INFECTION, WE PROPOSE TO INVESTIGATE A NOVEL STRATEGY OF VACCINATION AGAINST N. GONORRHOEAE, EXPLOITING NEUTRALIZING ANTIBODY AGAINST IL-10 ENCAPSULATED IN BIODEGRADABLE MICRO-PARTICLES (GNEXA10®) AS ADJUVANT. AS VACCINE ANTIGEN, OUTER MEMBRANE VESICLES (OMV) DERIVED FROM A DOUBLE- MUTANT (DM) STRAIN OF N. GONORRHOEAE, DESIGNED TO REDUCE ADVERSE RESPONSES TO ADMINISTRATION IN HUMANS, WILL BE USED. WE WILL DETERMINE THE ROLE OF SERUM AND MUCOSAL ANTIBODY AND T-CELL CYTOKINE RESPONSES TO INTRA-NASAL (I.N.) IMMUNIZATION WITH DMOMV PLUS GNEXA10®, IN RESISTANCE TO CHALLENGE INFECTION WITH BOTH HOMOLOGOUS AND HETEROLOGOUS STRAINS. PERSISTENCE OF IMMUNITY AND RECALL OF MEMORY RESPONSES AT INCREASING TIME INTERVALS AFTER IMMUNIZATION WILL BE EVALUATED. FUNCTIONAL ANTIBODIES ACTIVE AGAINST N. GONORRHOEAE WILL BE ASSESSED IN VITRO. THIS WORK WILL PROVIDE PROOF-OF-PRINCIPLE FOR A VACCINE BASED ON GONOCOCCAL DMOMVS AND GNEXA10®. FUTURE SBIR PHASE II STUDIES WILL FURTHER ELUCIDATE MECHANISMS OF CROSS-PROTECTION AGAINST DIVERSE STRAINS OF N. GONORRHOEAE, AND VALIDATE THE EXPECTED APPLICABILITY OF SCALED-UP VACCINE DEVELOPMENT, EVALUATING YIELD, BIOACTIVITY, BATCH-TO-BATCH CONSISTENCY, AND SHELF STABILITY. THIS PROPOSAL IS PART OF OUR COMPANY’S RESPONSE TO THE CDC’S AND WHO’S CALLS FOR DEVELOPMENT OF NOVEL VACCINE APPROACHES IN THE FACE OF THE PUBLIC HEALTH THREAT POSED BY ANTIBIOTIC-RESISTANT N. GONORRHOEAE.
Obligated Amount:
300000.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2019-07-31
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
ENCAPSULATED ANTI-IL-10 FOR THE IMMUNE THERAPY OF GONORRHEA INFECTION
Obligated Amount:
239162.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2019-03-07
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
IL-10NANOCAP? FOR THERAPY OF FAMILIAL ADENOMATOUS POLYPOSIS
Obligated Amount:
5216444.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2018-06-08
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
PLGA ENCAPSULATED POLYPHENOLS TO AMELIORATE IBD.
Obligated Amount:
320159.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2018-11-14
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
ORAL SUSTAINED-RELEASE IL-10 MICROSPHERES FOR THERAPY OF IBD
Obligated Amount:
295831.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks

Serial Number:
90312773
Mark:
FAPXIL
Status:
Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Mark Type:
Trademark
Application Filing Date:
2020-11-11
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
FAPXIL

Goods And Services

For:
Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents
International Classes:
005 - Primary Class
Class Status:
ACTIVE
Serial Number:
90309984
Mark:
ATRAXIM
Status:
Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Mark Type:
Trademark
Application Filing Date:
2020-11-10
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
ATRAXIM

Goods And Services

For:
Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Therapeutic pharmaceutical for the treatment of inflammatory bowel disease
International Classes:
005 - Primary Class
Class Status:
ACTIVE
Serial Number:
90309958
Mark:
PCX12
Status:
Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Mark Type:
Trademark
Application Filing Date:
2020-11-10
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
PCX12

Goods And Services

For:
Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer
International Classes:
005 - Primary Class
Class Status:
ACTIVE
Serial Number:
90307520
Mark:
NGOXIM
Status:
Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Mark Type:
Trademark
Application Filing Date:
2020-11-09
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
NGOXIM

Goods And Services

For:
Vaccine adjuvants; Vaccines
International Classes:
005 - Primary Class
Class Status:
ACTIVE
Serial Number:
90307501
Mark:
GNEX12
Status:
Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Mark Type:
Trademark
Application Filing Date:
2020-11-09
Mark Drawing Type:
4 - STANDARD CHARACTER MARK
Mark Literal Elements:
GNEX12

Goods And Services

For:
Adjuvants for use with vaccines; Human vaccine preparations; Therapeutic vaccines
International Classes:
005 - Primary Class
Class Status:
ACTIVE

Reviews Leave a review

This company hasn't received any reviews.

Financial Incentive

Program Program Status Average Hourly Wage Project Cost Incentive Amount Initial Jobs New Jobs Date of Action Approval Type
SBIR/STTR Inactive - $0 $150,000 - - 2015-07-01 Final

Sources: Kentucky Secretary of State